Golimumab and malignancies: true or false association?
Identifieur interne : 001719 ( Main/Exploration ); précédent : 001718; suivant : 001720Golimumab and malignancies: true or false association?
Auteurs : Ines Zidi [Tunisie] ; Aicha Bouaziz [Tunisie] ; Wissem Mnif [Tunisie] ; Aghleb Bartegi [Tunisie] ; Nidhal Ben Amor [Tunisie]Source :
- Medical Oncology [ 1357-0560 ] ; 2011-06-01.
Descripteurs français
- Wicri :
- topic : Cancer.
English descriptors
- KwdEn :
Abstract
Abstract: Malignancy is one of the comorbidities linked to golimumab, a biological TNF-α blocker. In this systematic review and meta-analysis, we searched different databases and analyzed original publications to elucidate the remaining open question about the real association of malignancies with golimumab therapy. The most frequent cancer in patients treated with golimumab, in association or not with methotrexate, is the lung adenocarcinoma. However, lymphoma is not very commonly represented in these patients. We show that there is no major and evident risk of malignancies associated with golimumab in current scientific literature. An increased risk of malignancies may be associated with golimumab, but this warrants further clinical confirmation. Also, this risk mentioned in different studies must be taken with caution because of number of limits and biases.
Url:
DOI: 10.1007/s12032-010-9490-7
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001842
- to stream Istex, to step Curation: 001842
- to stream Istex, to step Checkpoint: 000664
- to stream Main, to step Merge: 001722
- to stream Main, to step Curation: 001719
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Golimumab and malignancies: true or false association?</title><author><name sortKey="Zidi, Ines" sort="Zidi, Ines" uniqKey="Zidi I" first="Ines" last="Zidi">Ines Zidi</name></author><author><name sortKey="Bouaziz, Aicha" sort="Bouaziz, Aicha" uniqKey="Bouaziz A" first="Aicha" last="Bouaziz">Aicha Bouaziz</name></author><author><name sortKey="Mnif, Wissem" sort="Mnif, Wissem" uniqKey="Mnif W" first="Wissem" last="Mnif">Wissem Mnif</name></author><author><name sortKey="Bartegi, Aghleb" sort="Bartegi, Aghleb" uniqKey="Bartegi A" first="Aghleb" last="Bartegi">Aghleb Bartegi</name></author><author><name sortKey="Ben Amor, Nidhal" sort="Ben Amor, Nidhal" uniqKey="Ben Amor N" first="Nidhal" last="Ben Amor">Nidhal Ben Amor</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BF4A51F029A6E56BCF01F9A7EBC5133CE72947D4</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1007/s12032-010-9490-7</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-60QXHJQ3-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001842</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001842</idno><idno type="wicri:Area/Istex/Curation">001842</idno><idno type="wicri:Area/Istex/Checkpoint">000664</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000664</idno><idno type="wicri:doubleKey">1357-0560:2010:Zidi I:golimumab:and:malignancies</idno><idno type="wicri:Area/Main/Merge">001722</idno><idno type="wicri:Area/Main/Curation">001719</idno><idno type="wicri:Area/Main/Exploration">001719</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Golimumab and malignancies: true or false association?</title><author><name sortKey="Zidi, Ines" sort="Zidi, Ines" uniqKey="Zidi I" first="Ines" last="Zidi">Ines Zidi</name><affiliation wicri:level="1"><country xml:lang="fr">Tunisie</country><wicri:regionArea>Laboratory of Biochemistry, Research Unit 02/UR/09-01, Higher Institute of Biotechnology, BP 74, Avenue Tahar Haddad, 5000, Monastir</wicri:regionArea><wicri:noRegion>Monastir</wicri:noRegion></affiliation><affiliation></affiliation></author><author><name sortKey="Bouaziz, Aicha" sort="Bouaziz, Aicha" uniqKey="Bouaziz A" first="Aicha" last="Bouaziz">Aicha Bouaziz</name><affiliation wicri:level="1"><country xml:lang="fr">Tunisie</country><wicri:regionArea>Laboratory of Biochemistry, Research Unit 02/UR/09-01, Higher Institute of Biotechnology, BP 74, Avenue Tahar Haddad, 5000, Monastir</wicri:regionArea><wicri:noRegion>Monastir</wicri:noRegion></affiliation></author><author><name sortKey="Mnif, Wissem" sort="Mnif, Wissem" uniqKey="Mnif W" first="Wissem" last="Mnif">Wissem Mnif</name><affiliation wicri:level="1"><country xml:lang="fr">Tunisie</country><wicri:regionArea>Laboratory of Biochemistry, Research Unit 02/UR/09-01, Higher Institute of Biotechnology, BP 74, Avenue Tahar Haddad, 5000, Monastir</wicri:regionArea><wicri:noRegion>Monastir</wicri:noRegion></affiliation></author><author><name sortKey="Bartegi, Aghleb" sort="Bartegi, Aghleb" uniqKey="Bartegi A" first="Aghleb" last="Bartegi">Aghleb Bartegi</name><affiliation wicri:level="1"><country xml:lang="fr">Tunisie</country><wicri:regionArea>Laboratory of Biochemistry, Research Unit 02/UR/09-01, Higher Institute of Biotechnology, BP 74, Avenue Tahar Haddad, 5000, Monastir</wicri:regionArea><wicri:noRegion>Monastir</wicri:noRegion></affiliation></author><author><name sortKey="Ben Amor, Nidhal" sort="Ben Amor, Nidhal" uniqKey="Ben Amor N" first="Nidhal" last="Ben Amor">Nidhal Ben Amor</name><affiliation wicri:level="1"><country xml:lang="fr">Tunisie</country><wicri:regionArea>Laboratory of Biochemistry, Research Unit 02/UR/09-01, Higher Institute of Biotechnology, BP 74, Avenue Tahar Haddad, 5000, Monastir</wicri:regionArea><wicri:noRegion>Monastir</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Medical Oncology</title><title level="j" type="abbrev">Med Oncol</title><idno type="ISSN">1357-0560</idno><idno type="eISSN">1559-131X</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2011-06-01">2011-06-01</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="641">641</biblScope><biblScope unit="page" to="648">648</biblScope></imprint><idno type="ISSN">1357-0560</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1357-0560</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-TNF-alpha</term><term>Cancer</term><term>Golimumab</term><term>Methotrexate</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cancer</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Malignancy is one of the comorbidities linked to golimumab, a biological TNF-α blocker. In this systematic review and meta-analysis, we searched different databases and analyzed original publications to elucidate the remaining open question about the real association of malignancies with golimumab therapy. The most frequent cancer in patients treated with golimumab, in association or not with methotrexate, is the lung adenocarcinoma. However, lymphoma is not very commonly represented in these patients. We show that there is no major and evident risk of malignancies associated with golimumab in current scientific literature. An increased risk of malignancies may be associated with golimumab, but this warrants further clinical confirmation. Also, this risk mentioned in different studies must be taken with caution because of number of limits and biases.</div></front></TEI><affiliations><list><country><li>Tunisie</li></country></list><tree><country name="Tunisie"><noRegion><name sortKey="Zidi, Ines" sort="Zidi, Ines" uniqKey="Zidi I" first="Ines" last="Zidi">Ines Zidi</name></noRegion><name sortKey="Bartegi, Aghleb" sort="Bartegi, Aghleb" uniqKey="Bartegi A" first="Aghleb" last="Bartegi">Aghleb Bartegi</name><name sortKey="Ben Amor, Nidhal" sort="Ben Amor, Nidhal" uniqKey="Ben Amor N" first="Nidhal" last="Ben Amor">Nidhal Ben Amor</name><name sortKey="Bouaziz, Aicha" sort="Bouaziz, Aicha" uniqKey="Bouaziz A" first="Aicha" last="Bouaziz">Aicha Bouaziz</name><name sortKey="Mnif, Wissem" sort="Mnif, Wissem" uniqKey="Mnif W" first="Wissem" last="Mnif">Wissem Mnif</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001719 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001719 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BF4A51F029A6E56BCF01F9A7EBC5133CE72947D4
|texte= Golimumab and malignancies: true or false association?
}}
| This area was generated with Dilib version V0.6.33. |  |